4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
← catalyst calendarNCT06864988 · readout ≤ 315 d
Sponsored by 4D Molecular Therapeutics (industry) · FDMT — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
480estimated
Sites
95
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-03 | actual | When the study began enrolling |
| Primary completion | Jun 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Macular Neovascularization Secondary to Age-Related Macular Degeneration
Interventions
- Biological: 4D-150 IVT (3E10 vg/eye)
- Biological: EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Primary outcome
what the primary-completion date above is the date OFMean change from baseline in BCVA ETDRS letter score at Week 52
measured 52 Weeks
Permalink · FDMT's whole pipeline · Catalyst calendar · Every registered study · What changed